Relationships among serum C-reactive protein, receptor for advanced glycation products, metabolic dysfunction, and cognitive impairments

Xia Ge1, Xiao-yun Xu2*, Chun-hua Feng1, Yue Wang1, Yuan-ling Li1 and Bo Feng3

Abstract

Background: We examined the clinical value of two serum markers of low-grade inflammation, C-reactive protein (CRP) and receptor of advanced glycation products (RAGE), as prognostic indices for cognitive decline.

Methods: Patients with cognitive impairment (n = 377) and controls (n = 66) were examined by blood biochemistry tests, including ELISAs of serum CRP and RAGE, the Mini-mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA), and STEAM 1H-MRS of the left hippocampus and thalamus.

Results: Compared to the control group, the cognitive impairment group was older (63.10 ± 9.70 years vs. 55.09 ± 10.77 years, P = 0.000) and had fewer years of formal education (9.01 ± 4.01 vs. 12.94 ± 3.0, P = 0.000). There were no significant differences in the frequencies of type 2 diabetes, hypertension, or hyperlipidemia between groups. Serum CRP and RAGE were higher in the cognitive impairment group (CRP: 2.08 mg/L, range 1.07 – 3.36 mg/L vs. 0.21 mg/L, range 0.18 – 0.42 mg/L; RAGE: 4.01, range 2.49 – 5.71, vs. 2.28, range 1.84 – 3.03; P < 0.05 for both). In patients with cognitive impairment, there were negative correlations between cognitive function (as measured by MMSE and MoCA) and both CRP and RAGE levels (P < 0.05). Patients over 55 years exhibited a positive correlation between CRP and myo-inositol peak area in the left hippocampus (P < 0.05), while there was no relationship between RAGE and any metabolite (P > 0.05). Multiple linear regression revealed that CRP was influenced by hypertension (P = 0.026) and cognitive impairment (P = 0.042).

Conclusions: Chronic low-grade inflammation is present in patients with cognitive impairment. Serum CRP, RAGE, and left hippocampal myo-inositol may provide prognostic information on cognitive decline.

Background

Inflammation contributes to the development and exacerbation of cognitive decline in neurodegenerative diseases [1,2]. Individuals with C-reactive protein (CRP) concentrations > 3 mg/L are at significantly elevated risk for cardiovascular disease [3] while high-normal levels (2 ~ 3 mg/L) indicate low grade systemic inflammation [4]. Moreover, recent studies have established a correlation between serum CRP and cognitive impairment [5]. Another potential biological marker of cognitive decline, receptor for advanced glycation end products (RAGE), was first identified as a signal transduction receptor for the products of non-enzymatic glycation and oxidation of proteins and lipids (AGEs) that accumulate in diabetes and at inflammatory foci [6]. An association between RAGE levels and cognitive impairment in Alzheimer’s disease has been reported [7]. We evaluated the interrelationships among serum CRP, serum RAGE, neuropsychological assessment scores, and cerebral metabolites associated with cognitive dysfunction to examine the role of chronic low grade inflammation in cognitive decline and metabolic changes in brain structures, such as the hippocampus, critical for cognitive function.

* Correspondence: xxy195211@163.com
2Department of Neurology, Pudong New Area Zhoupu Hospital, Shanghai, China
Full list of author information is available at the end of the article

© 2013 Ge et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Methods

Patients

Patients assessed for cognitive decline at an out-patient department from September 2009 to November 2012 were recruited as the case group. Demographic parameters, including age and educational status, general medical condition as indicated by body mass index, personal and family histories of hypertension, type 2 diabetes, and stroke, and lifestyle risk factors such as smoking status, were recorded. Inclusion criteria included (1) cognitive decline for at least 6 months, (2) probable Alzheimer’s disease according to NINCDS-ADRDA criteria, (3) right handedness, and (4) Activity of Daily Living scale (ADL) score ≤ 26, Global Deterioration Scale (GDS) score ≤ 3, and Hamilton Depression scale (HAMD) score ≤ 7. Exclusion criteria included (1) sudden onset of cognitive decline, (2) history of neurological disease (e.g., large vessel stroke, Parkinson’s disease, severe brain injury, seizure, multiple sclerosis, brain infection, meningitis), (3) psychiatric illness (e.g., schizophrenia, bipolar disorder), (4) substance abuse (alcohol, drugs, or others), and (5) MRI contraindications. All the participants provided written informed consent before enrollment. In total, 377 patients were recruited as the patient group and 66 subjects without cognitive decline as the control group.

Assessments

Blood biochemistry

Fasting blood concentrations of glucose, glycosylated hemoglobin, total triglycerides, total cholesterol, HDL-cholesterol, LDL-cholesterol, apolipoprotein A, apolipoprotein B, and apolipoprotein E were detected by standard enzymatic assays. Radial artery blood pressure was measured by a standard blood pressure monitor (VP-2000, Colin Medical Technology Corporation, Japan) after at least 10 minutes of rest. Standard height and weight measurements were used to calculated patient BMI.

C-Reactive Protein (CRP) and RAGE assays

Serum concentrations of CRP and RAGE were measured by ELISA using 4 mL fasting blood drawn from the cubital vein into coagulating tubes. Serum aliquots were stored at −80°C until analysis. Prior to analysis, the serum sample was diluted 50-fold. Commercial ELISA kits for CRP (Human High sensitivity) were obtained from USCN Life Science and RAGE kits from BlueGene.

Neuropsychological evaluation

Cognitive assessments included the Mini-mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA). The MMSE consists of 10 items testing orientation, memory, attention, calculation, language (naming, repeating, auditory comprehension, reading, and writing) and visual-spatial ability, for a maximum total score of 30. The MoCA tests 8 cognitive domains, visual-spatial ability, attention, executive function, immediate memory, delayed memory, language, abstraction, calculation, and orientation, for a maximum total score of 30. The normal MoCA score is ≥26, with one point added if the subject has fewer than 12 years of formal education. All tests were administered and scored by a professional trained in neuropsychometric testing.

Neuroimaging

1H-MRS parameters were as follows: echo time/repetition time TE = 9.4 ms, TR = 2000 ms, 128 excitations, TA = 4 min 48 s, volume 1.0 cm3 from the left hippocampal gray matter and 1.5 cm3 from the left thalamic gray matter. These regions were chosen because many metabolites measured in these areas are related to cognitive disorders. The chosen volumes were able to cover the ROI as more as possible without mix of cerebral spinal fluid or other region, and results of region smaller than those above would cause deviation for slight move from inevitable breath and heartbeat. The concentrations of N-Acetyl-L-aspartic acid (NAA), choline-containing compounds, myo-inositol, and glutamate were measured and reported as peak area. All images were acquired by a professional radiology technician.

Data analyses

Data were analyzed using the Statistical Package for Social Sciences (SPSS 18.0). A two-tailed alpha level of 0.05 was the criterion for significance.

Ethics

All the process was approved by the ethics committees of Shanghai East Hospital Affiliated to Tongji University and the study was operated in accordance with the World Medical Association’s Declaration of Helsinki.

Results

A total of 443 participants were included in the final sample, 377 patients in the cognitive impairment group (178 men, 199 women) and 66 in the control group (38 men and 28 women). Demographic characteristics, indices of cardiovascular health and metabolic disease, and serum CRP and RAGE concentrations are presented in Table 1.

Correlation among serum CRP, cognitive function, and cerebral metabolism

Older age and lower education are generally accepted risk factors for cognitive dysfunction, and both were analyzed separately to avoid interference. Age was divided into 4 ranges: 40–54 (Figure 1), 55–64 (Figure 2), 65–79 (Figure 3), and > 80 years (Figure 4). Subjects were divided into two education groups according to whether
they had 12 years of formal education, as this is the cut-off used to correct MoCA scores. Correlations among CRP, cognitive function, and cerebral metabolites were analyzed by Spearman correlation in the 8 subgroups defined by the four age groups and two education groups.

Serum CRP was negatively correlated with MMSE and MoCA assessment scores ($p < 0.05$). There was a positive correlation between serum CRP and myo-inositol peak area in the left hippocampus ($p < 0.05$). Other metabolites measured by 1H-MRS were not significantly correlated with neuropsychological evaluation scores or CRP levels (Table 2).

### Correlations among serum RAGE, cognitive function, and cerebral metabolism

Serum RAGE was negatively correlated with MMSE and MoCA scores ($p < 0.05$). However, there was no significant negative correlation between serum RAGE and NAA peak area as predicted, or with any other metabolic changes in the left hippocampus (Table 3) or thalamus ($p > 0.05$) as measured by 1H-MRS.

### Multiple linear regression analysis of factor related to CRP

The effects of serum CRP and RAGE on cardiovascular parameters did not interact, so each was analyzed separately by multiple linear regression. There were no significant associations for RAGE, while stepwise regression showed that CRP was affected by hypertension ($p = 0.026$) and cognitive impairment ($p = 0.042$). The coefficient of determination of the regression analysis indicated that all

Table 1 Demographics, cardiovascular and metabolic health status, and serum CRP and RAGE levels in cognitively impaired patients and controls

|                      | Cognitive impairment  | Controls        | Z   | p      |
|----------------------|-----------------------|-----------------|-----|--------|
| Age (year)           | 63.10 ± 9.70          | 55.09 ± 10.77   | −5.295 | 0.000   |
| Gender (male)        | 178 (47.2%)           | 38 (57.6%)      | −1.256 | 0.209   |
| Education (year)     | 9.01 ± 4.01           | 12.94 ± 3.0     | −6.455 | 0.000   |
| CRP (mg/L)           | 2.08 (1.07, 3.36)     | 0.21 (0.18, 0.42) | −6.488 | 0.001   |
| RAGE (ng/mL)         | 4.01 (2.49, 5.71)     | 2.28 (1.84, 3.03) | −3.271 | 0.004   |
| Hypertension         | 60.5%                 | 54.5%           | −0.761 | 0.447   |
| Diabetes             | 28.8%                 | 38.7%           | −1.348 | 0.178   |
| Triglycerides (mmol/L) | 1.38 (0.89, 1.87)   | 1.49 (0.99, 2.06) | −0.831 | 0.406   |
| LDL (mmol/L)         | 2.93 (2.41, 3.68)     | 3.22 (2.67, 4.18) | −1.651 | 0.099   |
| Smoking              | 34.1%                 | 34.8%           | −0.151 | 0.880   |
| BMI (Kg/m$^2$)       | 23.58 ± 3.39          | 23.12 ± 2.63    | −0.189 | 0.850   |

Figure 1 Correlations among serum CRP levels, cognitive assessment, and myo-inositol in Age range: 40–54.
the variables (Table 4) accounted for 60.3% of the variability in serum CRP (p = 0.028).

Discussion
The clinical diagnosis of early stage cognitive impairment depends primarily on neuropsychological assessments because there are often no obvious structural lesions or metabolic changes in the brain as revealed by neuroimaging. Prognostic markers predictive of cognitive decline in the earliest stages prior to measureable impairments may facilitate timely intervention. Low grade inflammation is a possible contributing factor to cognitive decline and as such, indices of inflammation may be indicative of early pathogenic processes in brain regions associated with cognitive function. Pathological changes in the brain are often not reflected by changes in peripheral blood chemistry due to the blood brain barrier (BBB), but neural inflammation may be manifested by changes in peripheral blood if the BBB is disrupted by the pathology. Thus, it is possible that inflammatory mediators in peripheral blood may be the earliest signs of neurodegenerative disease. With this information as background, our target was to investigate the relationship between peripheral systemic inflammation and cerebral metabolism in AD cognitive decline.

Indeed, we found that inflammation as reflected by serum CRP was associated with cognition dysfunction. The median serum CRP in our cognitive impairment group was 2.08 mg/L, much higher than in the control sample (0.21 mg/L). Furthermore, CRP was inversely correlated with MMSE and MoCA scores in the total patient population and in subgroups stratified by age range and years of formal education (including the youngest higher-education group). Serum CRP is regarded as an independent risk factor for cardiovascular disease, and previous studies also suggested a relationship to cognitive decline [8-10], although no definitive mechanism has been established. If CRP is elevated before measurable cognitive decline, inflammation may contribute to cognitive impairment or accelerate the deterioration. For example, CRP can activate the complement system, causing a series of immune cascade reactions leading to neurodegeneration [11].

Serum CRP was also positively correlated with cerebral myo-inositol as indicated by 1H-MRS in subjects over 55 and independent of years of formal education. Myo-inositol is mainly found in astrocytes, and increases are indicative of glia proliferation as occurs in reactive gliosis [12]. Elevations of myo-inositol levels in Alzheimer’s disease patients have been interpreted as a sign of gliosis.
Astrocytes are phagocytic in the brain and spine and are induced to proliferate when the BBB is compromised. Potential mechanisms of these results were supposed to associate with the “leakage” of inflammation. Low-grade systemic inflammation mediated by CRP may lead to increased BBB permeability, impairment of endothelial function, and toxic elevations of intracellular calcium [14]. The intracellular second messenger inositol triphosphate (IP3) is not efficiently derived from myo-inositol and so may become depleted. This in turn would hinder calcium release and cause the failure of conduction through gap junctions between astrocytes, suppressing interstitial buffering functions and leading to neuronal hyperexcitability [15]. On the other hand, IP3 was found to associate with glioma by mediating signal transduction for activation and proliferation of gliocyte [16,17]. A compromised BBB may lead to release of inflammatory factors into the peripheral blood. Thus, the peripheral blood may contain markers indicative of neurodegenerative diseases like AD. But the precise connection between CRP and mI would be further studied and presented in future research.

Like CRP, RAGE is thought to impair cognition through an immune-inflammatory pathway. Yan [18] first found 2.5-fold RAGE overexpression in AD brains. Evidence suggests that RAGE expression is enhanced in the hippocampus and frontal lobe, and that RAGE binds to β-amyloid (Aβ) [19]. β-Amyloid can permeate the BBB from circulating blood by combining with RAGE in endothelial cells [20], triggering amyloid aggregation and stimulating a complex chronic immune-inflammatory response. This immune activation is neurotoxic and results in the pathological changes associated with AD [21]. The receptors RAGE, scavenger receptor, and serine protease inhibitor complex receptor (SEC-R) mediate the adherence of Aβ to microglia, which stimulates microglia activation. In turn, activated microglia release NO, TNF-α, TGF-β, and other cytotoxic factors [22]. Studies above all held the opinion that RAGE plays an important role in AD progression via immune and inflammation, while different from the cellular RAGE measured by immunohistochemical measurement in tissue, what our study chose was a quantitative determination of its total level in serum, which stood for the measurable RAGE in peripheral blood. More efficacious RAGE existed in serum meant more potential immune and inflammation by RAGE antigen-antibody reaction would happen. Another popular sample sRAGE (soluble receptor for advanced glycation end products), the competitive receptor against RAGE, is supposed to be a protective factor on AD cognition [23]. We would further study it and other else relevant receptors or ligands in sequence.

Figure 3 Correlations among serum CRP levels, cognitive assessment, and myo-inositol in Age range: 65–79.
Unexpectedly, we found no significant relationships between RAGE and diabetes, plasma glucose, or glycosylated hemoglobin. Cell activation due to AGE-RAGE interaction can occur in normal tissue via chronic immune inflammation, and this is aggravated in diabetes complications [24]. To date, however, the mechanism of cell activation in systemic diseases has not been defined. As expected, RAGE was much higher in the cognitive impairment group. Diabetes patients assigned in our study were the people without relevant complication, which might be involved in this result.

RAGE was not associated with any metabolic change in left hippocampus or thalamus. We predicted that RAGE may correlate with NAA, a sensitive neuroimaging biomarker indicative of neuronal integrity and function. In light of these results, we suggest that RAGE impairs cognition via immune signaling pathways that disrupt neuronal functions but do not damage neuronal

Table 2 Correlations among serum CRP levels, cognitive function, and cerebral metabolism

| Age group (years) | Education ≤12 | Education >12 |
|-------------------|---------------|---------------|
|                   | n | To MMSE | r | p | To MoCA | r | p | To myo-inositol | r | p |
| 40 – 54 ≤12       | 41 | −0.756 | 0.025 | −0.744 | 0.015 | 0.261 | 0.055 |
| >12               | 31 | −0.818 | 0.039 | −0.716 | 0.019 | 0.163 | 0.063 |
| 55 – 64 ≤12       | 88 | −0.672 | 0.021 | −0.707 | 0.011 | 0.712 | 0.026 |
| >12               | 47 | −0.724 | 0.022 | −0.738 | 0.023 | 0.747 | 0.029 |
| 65 – 79 ≤12       | 79 | −0.655 | 0.017 | −0.710 | 0.015 | 0.740 | 0.018 |
| >12               | 35 | −0.686 | 0.021 | −0.719 | 0.027 | 0.754 | 0.021 |
| >80               | 39 | −0.684 | 0.034 | −0.633 | 0.028 | 0.670 | 0.036 |
| >12               | 17 | −0.810 | 0.036 | −0.758 | 0.031 | 0.797 | 0.041 |

(Figures 1, 2, 3 and 4).

Table 3 Correlations among serum RAGE, cognitive function, and cerebral metabolism

| Age group (years) | Education ≤12 | Education >12 |
|-------------------|---------------|---------------|
|                   | n | To MMSE | r | p | To MoCA | r | p | To NAA | r | p |
| 40 – 54 ≤12       | 41 | −0.511 | 0.032 | −0.625 | 0.024 | −0.212 | 0.063 |
| >12               | 31 | −0.598 | 0.047 | −0.456 | 0.037 | −0.194 | 0.058 |
| 55 – 64 ≤12       | 88 | −0.563 | 0.041 | −0.604 | 0.028 | −0.235 | 0.072 |
| >12               | 47 | −0.492 | 0.038 | −0.462 | 0.033 | −0.186 | 0.062 |
| 65 – 79 ≤12       | 79 | −0.637 | 0.029 | −0.693 | 0.019 | −0.242 | 0.103 |
| >12               | 35 | −0.552 | 0.032 | −0.721 | 0.025 | −0.255 | 0.096 |
| >80               | 39 | −0.648 | 0.030 | −0.723 | 0.028 | −0.267 | 0.078 |
| >12               | 17 | −0.562 | 0.026 | −0.820 | 0.034 | −0.321 | 0.089 |
integrity. Elevations in NAA are indicative of cellular microtrauma. In AD or cerebral ischemia concomitant with myocardial infarction, metabolic changes such as NAA reduction and myo-inositol elevation can be detected in the hippocampus [25,26]. We hypothesized that participants with cognitive impairment would have higher serum CRP/RAGE and lower NAA, but found no significant association between serum RAGE and any biomarker of cerebral metabolism. Whether RAGE can effect cerebral metabolism is currently unknown, and we found no evidence for such an effect. Nonetheless, RAGE was associated with cognitive impairment, so a RAGE-mediated immune inflammatory reaction may cause cognitive impairment by highly localized effects on neurocircuits.

Regression analysis revealed that hypertension and cognitive impairment led to the elevation of CRP in serum. Serum CRP is widely believed to be an independent predictor of heart attack and stroke as well as an independent risk factor for hypertension [27,28]. Results from animal experiments indicate that low grade inflammation can damage endothelial cells and reduce the generation of NO, which results in the overexpression of angiotensin receptor-1 (AR-1). Overexpression of AR-1 activates the renin-angiotensin-aldosterone system and causes hypertension [29]. However, the precise relationship between CRP and hypertension remains unclear. In our study cohort, most of the hypertensive patients were clinically obese with characteristics of metabolic syndrome. Hypertension, obesity, hyperlipidemia, and diabetes, the main manifestations of metabolic syndrome, do not always present simultaneously, while in obese patients, the presence of at least three of these manifestations can lead to CRP elevation [30]. Hypertension is a significant predictor of cardiovascular events and is strongly association with inflammation by CRP.

We found no interrelationship between the level of serum CRP and myo-inositol or other metabolites in the left hippocampus of hypertensives stratified by disease severity with or without cognitive impairment. Though CRP was higher in hypertension patients, there was no correlation between CRP (or RAGE) and brain metabolites related to inflammation. However, there has been little research on the influence of long-term chronic hypertension on the blood brain barrier and glial responses, so it is possible that CRP does not cross the BBB even if brain inflammation is present.

The cognitive impairment group was older than the control group and had fewer years of formal education, suggesting that a “cognitive reserve” in unafflicted individuals may prevent or mask cognitive impairment [31,32]. There were no significant differences in the frequencies of type 2 diabetes, hypertension, or hyperlipidemia between groups. Among these diseases, type 2 diabetes has been shown to negatively affect cognitive function [33] but there was no difference in diabetes incidence, plasma glucose, or glycosylated hemoglobin between groups. As metabolic syndrome progresses, diabetes coexists with hypertension, hyperlipidemia, and even obesity, leading to a low-grade inflammatory condition that ultimately impairs cognition [1]. The participants assigned to the cognitive impairment group were mostly in the early stages and demonstrated relatively mild impairments. Moreover, one of our objectives was to assess risk factors for cerebrovascular and cardiovascular diseases, and almost all patients accepted appropriate treatments. This early intervention may have contributed to the relatively mild effects on cognition.

Conclusions

We found significant correlations between cognitive impairment and inflammatory markers in the peripheral circulation. Thus, we have identified a possible non-invasive method for detecting neuro-inflammation leading to cognitive dysfunction. One limitation of this study is that we only detected two markers. Future studies will assess additional markers, including interleukins, TNF, interferon, and complement together in a larger patient sample.

In sum, our data provide evidence that relatively high levels of serum CRP and RAGE have a negative impact on cognitive function. Additionally, there is a positive correlation between serum CRP and myo-inositol in the left hippocampus. Thus, serum CRP, RAGE, and myo-inositol in the left hippocampus are candidate biomarkers for cognitive diseases that warrant validation in future studies.

Competing interests

The authors declare that they have no competing interest.
Authors’ contributions
GX and XXY conceived the study and drafted the manuscript. GX also carried out all data analyses and wrote the paper. GX, FCH, WY and LYL participated in information collection, cognitive assessment, MRS scans and acquisition of data. XXY is the principal investigator for the overall program grant. All authors read and approved the final manuscript.

Acknowledgements
We are grateful to Prof. Xiao-yun Xu, for helpful discussion and encouragement and financial support by her scientific research funds. We are also grateful to Prof. Bo Feng, teachers Yue Wang, and my colleagues Chun-hua Feng and Yuan liing Li who were involved in design, collection and analysis of the research. We are also grateful to all clinical research coordinators for their help in obtaining informed consent and collecting clinical data.

Author details
1Department of Neurology, East Hospital, Tongji University, Shanghai, China.
2Department of Neurology, Pudong New Area Zhoupou Hospital, Shanghai, China.
3Department of Endocrinology, East Hospital, Tongji University, Shanghai, China.

Received: 14 April 2013 Accepted: 21 August 2013
Published: 27 August 2013

References
1. Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, Tylavsky FA, Newman AB: The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004, 292:2237–2242.
2. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ: Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002, 52:168–174.
3. Dali-Youcef N, Mecili M, Ricci R, Andres E: Inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002, 59:499–511.
4. Ravaglia G, Forti P, Maiali F, Chiappelli M, Montesi F, Turchini E, Mariani E, Licastro F, Patterson C: Blood inflammatory markers and risk of dementia: the conselice study of brain aging. Neurobiol Aging 2007, 28:1810–1820.
5. Ramasamy R, Yan SF, Schmidt AM: Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci 2011, 1243:86–102.
6. Deane R, Zlokovic BV: Role of the blood–brain barrier in the pathogenesis of Alzheimer’s disease. Curr Alzheimer Res 2007, 4:197–191.
7. Yaffe K, Lindquist K, Penninx BW, Simonsick EM, Pahor M, Kitchevsky S, Launer L, Kuller L, Rubini S, Harris T: Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 2003, 61:78–80.
8. Teunissen CE, van Bokel MP, Bosma H, Bosmans E, Delanghe J, De Bruyn C, Wautea A, Maes M, Selens JB, Huysmans MP: Elevated serum C-reactive protein relates to increased cerebral myoinositol levels in middle-aged adults. Cardiovascular Psychiatry and Neurology 2012, 2012:20540.
9. Martin WR: MR spectroscopy in neurodegenerative disease. Mol Imaging Biol 2007, 9:196–203.
10. Kantarci K, Jack CR Jr, Xu YC, Campeau NG, O’Brien PC, Smith GE, Jnwk RJ, Boeve BF, Kolmen E, Tangalos EG, Petersen RC: Regional metabolic patterns in mild cognitive impairment and Alzheimer’s disease: a 1H MRS study. Neurology 2000, 55:210–217.
11. Abbott NJ: Astrocyte-endothelial interactions and blood–brain barrier permeability. J Anat 2003, 200:629–638.
12. Martin WR: MR spectroscopy in neurodegenerative disease. Mol Imaging Biol 2007, 9:196–203.
13. Eagan DE, Gonzales MM, Tanum T, Tanaka H, Strauberg S, Haley AP: Elevated serum C-reactive protein relates to increased cerebral myoinositol levels in middle-aged adults. Cardiovascular Psychiatry and Neurology 2012, 2012:20540.
14. Abbott NJ: Astrocyte-endothelial interactions and blood–brain barrier permeability. J Anat 2003, 200:629–638.
15. Cheung KH, Shneman D, Muller M, Cardenas C, M, L, Yang J, Tornita M, Iwatsubo T, Lee VM, Fossett JK: Mechanism of Ca2+ disruption in Alzheimer’s disease by preseilin regulation of InsP3 receptor channel gating. Neuroph 2008, 38:871–883.
16. Brandes AA, Franceschi E, Tosoni A, Hegi ME, Stupp R: Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. Clinical Cancer Res 2008, 14,597–560.
17. Paz-Ares L, Blanco-Aparicio C, Garcia-Carbonero R, Camero A: Inhibiting PI3K as a therapeutic strategy against cancer. Clinical And Translational Oncol 2009, 11:572–579.
18. Yan SD, Chen F, Chen M, Zhu H, Hofer A, Slattery T, Zhao L, Nakagawa M, Møller S, Migliel A, Nafroth P, Stern D, Schmidt AM: RAGE and amyloid-beta peptide neurotoxicity in Alzheimer’s disease. Nature 1996, 382:685–691.
19. Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, Schmidt AM, Stern DM, Yan SD: Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer’s disease: identification of a cellular activation mechanism. Exp Neurol 2001, 171:29–45.
20. Deane R, Yu S, Subiramanyan RK, Lalère B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Oi C, Friangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Lifensiek B, Nafroth P, Hofman F, Kindy M, Stern D, Zlokovic B: RAGE mediates amyloid-beta peptide transport across the blood–brain barrier and accumulation in brain. Nat Med 2003, 9:907–913.
21. Du Yan S, Zhu H, Yu J, Yan SF, Roher A, Tourtellotte WJ, Rajavashist T, Chen X, Godman GC, Stern D, Schmidt AM: Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci U S A 1997, 94:5266–5271.
22. Mattson MP: Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 2000, 1:120–129.
23. Giordino R, Benusis L, Glionsa M, Franconz M, Geroldi D, Erranuette E, Binetti G: Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment. Journal of neural transm 2008, 115:1047–1050.
24. Tani N, Markowitz GS, Fu C, Kiiising R, Taguchi A, Pischetsrieder M, Stern D, Schmidt AM, D’Agati VD: Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2001, 11:1656–1666.
25. Walecki J, Barczkowska M, Cwkl JB, Gabryelevicz T: N-acetylasparatate, choline, myoinositol, glutamine and glutamate (gln) concentration changes in prion MR spectroscopy (1H MRS) in patients with mild cognitive impairment (MCI). Med Sci Monit 2011, 17:MT205–111.
26. Foy CM, Daly EM, Glover A, O’Gorman R, Simmons A, Murphy DG, Lozestore S: Hippocampal prion MR spectroscopy in early Alzheimer’s disease and mild cognitive impairment. Brain Topogr 2011, 24:316–322.
27. Sesso HD, Buring JE, Rifai N, Blake GJ, Gazzino JM, Ridker PM: C-reactive protein and the risk of developing hypertension. JAMA 2003, 290:2945–2951.
28. Kalmijn S, Foly S, Burchfeld CM, Wellon R, Hoss GW, Haflik R, Launer L: Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study. Arterioscler Thromb Vasc Biol 2000, 20:2255–2260.
29. Verma S, Wang CH, Li SH, Weisell RD, Li RK, Mickle DA, Stewart DJ: A self-fuelling prophyphy: C-reactive protein attenuates nitric oxide production and inhibits angiogenicity. Circulation 2002, 106:913–919.
30. Berti PM, Berti IE, Cook JD: Circulating C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003, 107:391–397.
31. McGeer EG, McGeer PL: Brain inflammation in Alzheimer disease and the therapeutic implications. Curr Pharm Des 1999, 5:821–836.
32. Stern Y: What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc 2002, 8:468–466.
33. Luchsinger JA: Type 2 diabetes and cognitive impairment: linking mechanisms. J Alzheimers Dis 2012, 30Suppl 2:1585–198.

Cite this article as: Ge et al.: Relationships among serum C-reactive protein, receptor for advanced glycation products, metabolic dysfunction, and cognitive impairments. BMC Neurology 2013:13.